SCHEMBL1130998

SCHEMBL1130998

COC(=O)C1CC(n2nnc(-c3ccc(F)cc3F)n2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.45
CDK9 P50750 1/20 0.45
ABL1 P00519 6/20 0.39
BCR P11274 6/20 0.39
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
P2RX3 P56373 1/20 0.36
USP30 Q70CQ3 1/20 0.35
PTPN1 P18031 1/20 0.35
HDAC1 Q13547 3/20 0.34
HDAC8 Q9BY41 3/20 0.34
HDAC6 Q9UBN7 3/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
MKNK1 Q9BUB5 1/20 0.33
ACKR3 P25106 1/20 0.33
BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1130935 1.00 CCNT1 (0.45) CCNT1CDK9ABL1BCRNR1H2
SCHEMBL3892192 0.91 ABL1 (0.37) CCNT1CDK9ABL1BCRP2RX3
SCHEMBL1131373 0.81 ALDH1A1 (0.41) CCNT1CDK9NR1H2NR1H3USP30
SCHEMBL10255074 0.81 ALDH1A1 (0.41) CCNT1CDK9NR1H2NR1H3USP30
SCHEMBL31563787 0.79 SMN1; SMN2 (0.47) POLB
SCHEMBL3903362 0.79 GPR119 (0.40)
SCHEMBL1131590 0.79 GPR119 (0.40)
SCHEMBL10254818 0.73 NR1H2 (0.43) CCNT1CDK9ABL1BCRNR1H2
SCHEMBL24739225 0.73 CCNT1 (0.44) CCNT1CDK9NR1H2NR1H3P2RX3
SCHEMBL5152159 0.73 CCNT1 (0.44) CCNT1CDK9NR1H2NR1H3P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155729-B1 PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-02-16 EP disclosed
EP-2155729-A1 PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
US-7501422-B2 Prolinamide-tetrazole derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2009-03-10 US disclosed
US-20080306089-A1 PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMAN-LA ROCHE AG (CH) 2008-12-11 US disclosed
WO-2008148688-A1 PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306089-A1 PROLINAMIDE-TETRAZOLE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS SLC6A3, TAC3, NPSR1 CCNT1 2291/4885CDK9 1039/4885ABL1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.